As the real function of M2 macrophages in the development of atherosclerosis remains unclear, in vivo studies using PAFR antagonists are needed before suggesting their use as a therapeutic approach for the treatment of atherosclerosis. This evidence concerns the gene PTAFR and atherosclerosis.